Celldex, Oncothyreon Inc. deal

Oncothyreon will conduct and fund an open-label Phase Ib trial evaluating the company's ONT-10 with Celldex's varlilumab in up to 42 patients with advanced breast or ovarian cancer. Celldex referred ...